compare glp 1 GLP-1 vs. GLP-1 + GIP: What's the Difference for your Metabolism? Metabolic Axis Rx Trends: Real-World Data on

Professor Goldsteins research contributions include: Co-discovery and isolation of the thymosin family of peptides in the 1960s First clinical trials of thymosin preparations in immunodeficient children (1974) Characterization of thymosin beta-4s actin-binding and wound healing properties Development of therapeutic applications for tissue repair and regeneration Over 450 published scientific articles and 25+ patents related to thymosins Leadership in translating thymosin research toward clinical development Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to BPC-157 and TB-500/thymosin beta-4 research

Patients with F2F3 fibrosis may be candidates for FDA-approved resmetirom

In the SURMOUNT-1 trial, treatment discontinuation rates due to adverse events were 4.3% for the 5 mg group, 7.1% for the 10 mg group, and 6.2% for the 15 mg group

Sansregret, L., Vanhaesebroeck, B

This guide breaks it down

The most serious risk, lactic acidosis, is extremely rare (estimated at 1-5 cases per 100,000 patient-years) and occurs almost exclusively in patients with severe kidney impairment or acute illness